LARRY W TSAI, MD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 159473
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
75 Brigham And WOMEN'S HOSPITAL PULMONARY DIVISION, Boston, MA 02115
Phone
(617) 732-5500
(617) 732-7420
(617) 732-7420
Personal information
See more information about LARRY W TSAI at radaris.comName
Address
Phone
15 Braddock Park #1, Boston, MA 02116
14 Chiswick Rd, Brighton, MA 02135
8 Garrison St, Boston, MA 02116
454 Beacon St, Boston, MA 02115
48 Saint Germain St, Boston, MA 02115
Professional information
Dr. Larry W Tsai, Boston MA - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
BRIGHAM WOMENS HOSPITAL
75 Francis St, Boston 02115
(617) 732-5500 (Phone), (617) 525-6554 (Fax)
75 Francis St, Boston 02115
(617) 732-5500 (Phone), (617) 525-6554 (Fax)
Certifications:
Critical Care Medicine, 2013, Internal Medicine, 2010, Pulmonary Disease, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
BRIGHAM WOMENS HOSPITAL
75 Francis St, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
75 Francis St, Boston 02115
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
Harvard Medical School
Graduated: 1997
Brigham and Womens Hospital
University Of California-San Francisco
Harvard Medical School
Graduated: 1997
Brigham and Womens Hospital
University Of California-San Francisco
Vp Research/Medical Director At Aeris Therapeutics
Position:
VP Research and Development at Aeris Therapeutics, Medical Director at Aeris Therapeutics
Location:
Greater Boston Area
Industry:
Biotechnology
Work:
Aeris Therapeutics
since Jan 2011
-
VP Research and Development
Aeris Therapeutics
since Jan 2009
-
Medical Director
Brigham and Women's Hospital
2004 - 2013
-
Staff Physician
Education:
University of California, San Francisco 2000 - 2001
Fellowship, Pulmonary and Critical Care Medicine Harvard Medical School
Doctor of Medicine (MD) Stanford University
Bachelor of Science (BS)
Fellowship, Pulmonary and Critical Care Medicine Harvard Medical School
Doctor of Medicine (MD) Stanford University
Bachelor of Science (BS)
Vp Research/Medical Director At Aeris Therapeutics
Position:
VP Research and Development at Aeris Therapeutics, Medical Director at Aeris Therapeutics
Location:
Greater Boston Area
Industry:
Biotechnology
Work:
Aeris Therapeutics
since Jan 2011
-
VP Research and Development
Aeris Therapeutics
since Jan 2009
-
Medical Director
Brigham and Women's Hospital
2004 - 2013
-
Staff Physician
Education:
University of California, San Francisco 2000 - 2001
Fellowship, Pulmonary and Critical Care Medicine Harvard Medical School
Doctor of Medicine (MD) Stanford University
Bachelor of Science (BS)
Fellowship, Pulmonary and Critical Care Medicine Harvard Medical School
Doctor of Medicine (MD) Stanford University
Bachelor of Science (BS)
Larry Wilse Tsai, Boston MA
Specialties:
Internal Medicine, Critical Care Medicine, Pulmonary Disease, Critical Care Medicine
Work:
Brigham and Women's Hospital
75 Francis St, Boston, MA 02115
75 Francis St, Boston, MA 02115
Education:
Harvard University(1997)
Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers
US Patent:
8198365, Jun 12, 2012
Filed:
May 8, 2008
Appl. No.:
12/117367
Inventors:
Edward P. Ingenito - North Quincy MA, US
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Assignee:
Aeris Therapeutics, LLC - Woburn MA
International Classification:
C08F 8/00
US Classification:
525 61, 525 56, 528425, 604 28
Abstract:
One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e. g. , blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
Polymer Systems For Lung Volume Reduction Therapy
US Patent:
8361484, Jan 29, 2013
Filed:
Sep 27, 2007
Appl. No.:
12/443021
Inventors:
Edward P. Ingenito - North Quincy MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Assignee:
Aeris Therapeutics, Inc. - Woburn MA
International Classification:
A61K 9/00
US Classification:
424400, 424 7808, 424 7817, 424 7818, 424 7831
Abstract:
One aspect of the invention relates to a hydrogel comprising a polymer comprising a plurality of pendent hydroxyl groups, a crosslinker, and a sclerosing agent. Another aspect of the invention relates to a method for reducing lung volume in a patient comprising the steps of advancing into a region of a patient's lung via said patient's trachea a multi-lumen catheter lumen through a bronchoscope; and co-administering, through the multi-lumen catheter, a first mixture comprising a first amount of a polymer containing a plurality of pendent hydroxyl groups; a second mixture comprising a second amount of a crosslinker; and a third mixture comprising a third amount of a sclerosing agent; thereby forming a hydrogel in said region. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema of the lung.
Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers
US Patent:
8445589, May 21, 2013
Filed:
Jun 11, 2012
Appl. No.:
13/493409
Inventors:
Edward P. Ingenito - North Quincy MA, US
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Assignee:
Aeris Therapeutics, LLC - Woburn MA
International Classification:
C08F 8/00
US Classification:
525 61, 525 56, 528425, 604 28
Abstract:
One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e. g. , blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
Polycation-Polyanion Complexes, Compositions And Methods Of Use Thereof
US Patent:
2007011, May 17, 2007
Filed:
Oct 31, 2006
Appl. No.:
11/590664
Inventors:
Edward Ingenito - North Quincy MA, US
Alexander Schwarz - Brookline MA, US
Larry Tsai - Boston MA, US
Alexander Schwarz - Brookline MA, US
Larry Tsai - Boston MA, US
Assignee:
AERIS THERAPEUTICS, INC. - Wobum MA
International Classification:
A61K 38/48, A61K 9/14
US Classification:
424488000, 514012000, 424094640
Abstract:
One aspect of the present invention relates to compositions and methods comprising polyelectrolyte molecules for treating patients who have certain diseases. Aspects of the invention relate to using certain polyelectrolyte compositions in therapy. According to the invention polyelectrolyte compositions may be used, for example, to slow or stop cell growth, kill cells (e.g., via necrotic or apoptotic pathways), promote fibrosis, or a combination thereof. In one aspect of the invention, certain toxic (e.g., cytotoxic) properties of polyelectrolytes are exploited for therapeutic purposes. In certain embodiments, compositions and methods of the invention are used to target polyelectrolyte toxicity to predetermined regions within a subject, while minimizing undesirable toxicity at other regions with the subject. In certain embodiments, the present invention relates to lung-volume-reduction therapy using a polyelectrolyte composition.
Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers
US Patent:
2013032, Dec 5, 2013
Filed:
May 21, 2013
Appl. No.:
13/898624
Inventors:
James A. Krom - Belmont MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Alexander Schwarz - Brookline MA, US
Larry W. Tsai - Boston MA, US
Assignee:
Aeris Therapeutics, LLC - Woburn MA
International Classification:
A61L 24/04, A61L 24/00
US Classification:
606214
Abstract:
One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.
Lung Volume Reduction Therapy Using Crosslinked Biopolymers
US Patent:
2008026, Oct 23, 2008
Filed:
Apr 3, 2008
Appl. No.:
12/062189
Inventors:
Larry W. Tsai - Boston MA, US
Edward P. Ingenito - North Quincy MA, US
Edward P. Ingenito - North Quincy MA, US
Assignee:
AERIS THERAPEUTICS, INC. - Woburn MA
International Classification:
A61K 38/38, A61P 11/00
US Classification:
514 12
Abstract:
One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels.